Rijpkema, Bas (2025) The Renin–Angiotensin System in Cancer: Mechanisms of Tumor Enhancement and Inhibition and Therapeutic Targets. Bachelor's Thesis, Biology.
|
Text
WBBY901-052025RijpkemaBD.pdf Download (5MB) | Preview |
|
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
Toestemming.pdf Restricted to Registered users only Download (189kB) |
Abstract
The renin–angiotensin system (RAS), traditionally known for its role in cardiovascular regulation, is increasingly recognized as a modulator of cancer biology. This thesis explores the dual role of RAS in oncology, i.e. on the one hand in tumor tumorigenesis / development and on the other hand in tumor suppression and evaluates its components as potential therapeutic targets. The classical RAS axis (ACE–Ang II–AT₁R) promotes tumor growth through activation of oncogenic pathways, angiogenesis, inflammation, and immune evasion. Conversely, the counter-regulatory arm—comprising ACE2, Ang-(1-5), Ang-(1–7), presumably the Mas receptor, and certainly AT₂R—exerts anti-proliferative and pro-apoptotic effects. Particular focus is given to the therapeutic potential of modulating these opposing pathways. While AT₁R antagonists and ACE inhibitors show promise in reducing tumor progression, AT₂R agonists and Ang-(1–7) may enhance tumor suppression. Recent evidence challenges the interaction of Ang-(1–7) with MasR, suggesting alternative mechanisms. This thesis proposes that Ang-(1–5), a downstream metabolite of Ang-(1–7), might induce these suppressive effects, either through MasR or AT₂R. Overall, dual modulation of RAS—suppressing pro-tumor and enhancing anti-tumor axes—represents a promising avenue for cancer therapy.
| Item Type: | Thesis (Bachelor's Thesis) |
|---|---|
| Supervisor name: | Moll, G.N. |
| Degree programme: | Biology |
| Thesis type: | Bachelor's Thesis |
| Language: | English |
| Date Deposited: | 02 Jul 2025 10:33 |
| Last Modified: | 02 Jul 2025 10:33 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/35736 |
Actions (login required)
 |
View Item |